Last reviewed · How we verify
Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals
Background: Human immunodeficiency virus (HIV) affects the immune system. The main function of the immune system is protect you from infections and other diseases such as cancer. HIV attacks and cripples the immune system making people more susceptible to a variety of infections and cancers. Currently, the standard treatment for HIV infection is a daily administration of anti-HIV drugs. These drugs are called combination antiretroviral therapy (ART). ART is very effective at suppressing HIV, but does not cure HIV infection. ART must be taken continuously for life to be effective. ART can stop being effective if not taken correctly and can cause permanent side effects. Researchers want to see if two new products can control HIV infection without the use of ART. The products are the antibodies 3BNC117 and 10-1074. Objective: To see if 3BNC117 and 10-1074 are safe and can control HIV levels in the blood of people who are not taking ART or people who stop taking their ART during the study. . Eligibility: Adults ages 18-65 with HIV who are: * on ART and willing to stop treatment for at least 28 weeks * OR not taking ART with low levels of HIV in the blood Design: Participants will be screened with a physical exam, medical history, and blood, heart, and urine tests. Participants will get the 2 study products or salt water (placebo). A thin tube will be placed in an arm vein. Each product will be given directly into the vein for about 1 hour. To help collect blood cells to study in the laboratory, participants may have a procedure known as leukapheresis in which blood will be removed through a needle in the arm. Some of the white blood cells will be separated from the blood and used for research studies to see how 3BNC117 and 10-1074 effects HIV and the immune system. The rest of the blood will be returned to the person through another needle in the arm. Participants will have 18 study visits over 28 weeks. They will repeat some screening tests. They may have leukapheresis again. At 8 study visits, participants will get the study products or placebo. All participants will be followed for at least 24 weeks after their last dose of the study infusions. Participants who are in the Group that stops ART will be monitored closely to make sure the levels of virus in their blood do not go to high. If at any time during this the study a person develops HIV-related symptoms, or if the viral levels go up to high levels for more than 4 weeks, ART will be restarted and no further infusions of 3BNC117 and 10-1074 will be given. ...
Details
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
|---|---|
| Phase | PHASE1 |
| Status | TERMINATED |
| Enrolment | 27 |
| Start date | Mon Sep 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Mar 29 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- HIV
Interventions
- 3BNC117 and 10-1074
- Placebo
Countries
United States